PDF(Pubmed)
Abstract：
UNASSIGNED: Response to the current available treatments of melasma, dermal type, in particular, is usually gradual and can result in possible side effects.
UNASSIGNED: In this study, we aim to evaluate the efficacy of the combination of plasma rich in growth factors (PRGF) and topical 4% hydroquinone (HQ) in comparison with monotherapy using topical 4% HQ alone in the treatment of dermal type of melasma.
UNASSIGNED: This is a single-blinded, randomized, split-face clinical trial on twenty female patients with dermal type of melasma. Patients were asked to apply topical 4% HQ on both sides of their face at night for 6 months. In each participant, one side of the face was randomly chosen to receive monthly intradermal injections of PRGF for 3 sessions. Efficacy of the treatment was assessed using hemi melasma area and severity index (MASI) score, physician\'s global assessment (PGA), and patients\' global assessment (PtGA).
UNASSIGNED: Both groups revealed significant improvement in hemi-MASI score during the treatment course. Mean percentage of improvement at the end of study was 40.38 ± 6.04% and 33.42 ± 3.23% in the combination therapy and monotherapy groups, respectively (P = 0.31). PGA demonstrated excellent-to-marked improvement in melasma in 25% and 5% of patients in the combination therapy and monotherapy groups, respectively (P = 0.31). PtGA showed high levels of satisfaction in 15% of patients in the combination therapy group (vs. 0% in the monotherapy group) (P = 0.05).
UNASSIGNED: Differences between the two treatment groups in terms of hemi-MASI and PGA scores were not statistically significant; however, patients demonstrated higher satisfaction with combination of PRGF and topical 4% HQ compared with topical HQ alone. Thereby, combination of PRGF and topical 4% HQ can be suggested as a safe alternative therapeutic approach and may hold promise in the development of future therapeutic options for dermal type of melasma.
UNASSIGNED: In this study, we aim to evaluate the efficacy of the combination of plasma rich in growth factors (PRGF) and topical 4% hydroquinone (HQ) in comparison with monotherapy using topical 4% HQ alone in the treatment of dermal type of melasma.
UNASSIGNED: This is a single-blinded, randomized, split-face clinical trial on twenty female patients with dermal type of melasma. Patients were asked to apply topical 4% HQ on both sides of their face at night for 6 months. In each participant, one side of the face was randomly chosen to receive monthly intradermal injections of PRGF for 3 sessions. Efficacy of the treatment was assessed using hemi melasma area and severity index (MASI) score, physician\'s global assessment (PGA), and patients\' global assessment (PtGA).
UNASSIGNED: Both groups revealed significant improvement in hemi-MASI score during the treatment course. Mean percentage of improvement at the end of study was 40.38 ± 6.04% and 33.42 ± 3.23% in the combination therapy and monotherapy groups, respectively (P = 0.31). PGA demonstrated excellent-to-marked improvement in melasma in 25% and 5% of patients in the combination therapy and monotherapy groups, respectively (P = 0.31). PtGA showed high levels of satisfaction in 15% of patients in the combination therapy group (vs. 0% in the monotherapy group) (P = 0.05).
UNASSIGNED: Differences between the two treatment groups in terms of hemi-MASI and PGA scores were not statistically significant; however, patients demonstrated higher satisfaction with combination of PRGF and topical 4% HQ compared with topical HQ alone. Thereby, combination of PRGF and topical 4% HQ can be suggested as a safe alternative therapeutic approach and may hold promise in the development of future therapeutic options for dermal type of melasma.
摘要：
■对当前可用的黄褐斑治疗的反应，真皮型,特别是,通常是渐进的，可能会导致可能的副作用。
■在这项研究中，我们的目的是评估富含生长因子的血浆(PRGF)和局部4%氢醌(HQ)联合治疗与单独使用局部4%HQ的单药治疗皮肤型黄褐斑的疗效.
■这是一个单盲，随机化，20例皮肤型黄褐斑女性患者的分面临床试验。要求患者在夜间在面部两侧局部施用4％HQ，持续6个月。在每个参与者中，我们随机选择一侧面部接受3次PRGF的每月皮内注射.使用半黄褐斑面积和严重程度指数（MASI）评分评估治疗效果，医师全球评估(PGA)，和患者全球评估(PtGA)。
■两组均显示治疗过程中半MASI评分的显着改善。在联合治疗和单一治疗组中，研究结束时的平均改善百分比为40.38±6.04%和33.42±3.23%。分别为(P=0.31)。在联合治疗和单一治疗组中，PGA在25％和5％的患者中显示出黄褐斑的显着改善，分别为(P=0.31)。PtGA在联合治疗组中15％的患者中显示出较高的满意度（与单药治疗组为0％（P=0.05）。
■两个治疗组在hemi-MASI和PGA评分方面的差异无统计学意义；然而，与单独使用局部HQ相比,患者对PRGF和外用4%HQ的组合表现出更高的满意度.因此，PRGF和外用4%HQ联合治疗可被认为是一种安全的替代治疗方法,并有望为皮肤型黄褐斑的未来治疗方案的开发提供依据.
■在这项研究中，我们的目的是评估富含生长因子的血浆(PRGF)和局部4%氢醌(HQ)联合治疗与单独使用局部4%HQ的单药治疗皮肤型黄褐斑的疗效.
■这是一个单盲，随机化，20例皮肤型黄褐斑女性患者的分面临床试验。要求患者在夜间在面部两侧局部施用4％HQ，持续6个月。在每个参与者中，我们随机选择一侧面部接受3次PRGF的每月皮内注射.使用半黄褐斑面积和严重程度指数（MASI）评分评估治疗效果，医师全球评估(PGA)，和患者全球评估(PtGA)。
■两组均显示治疗过程中半MASI评分的显着改善。在联合治疗和单一治疗组中，研究结束时的平均改善百分比为40.38±6.04%和33.42±3.23%。分别为(P=0.31)。在联合治疗和单一治疗组中，PGA在25％和5％的患者中显示出黄褐斑的显着改善，分别为(P=0.31)。PtGA在联合治疗组中15％的患者中显示出较高的满意度（与单药治疗组为0％（P=0.05）。
■两个治疗组在hemi-MASI和PGA评分方面的差异无统计学意义；然而，与单独使用局部HQ相比,患者对PRGF和外用4%HQ的组合表现出更高的满意度.因此，PRGF和外用4%HQ联合治疗可被认为是一种安全的替代治疗方法,并有望为皮肤型黄褐斑的未来治疗方案的开发提供依据.
